《艾昆纬&Reset Health：2025英国抗肥胖药物临床应用的成本控制与服务优化白皮书（英文版）（13页）.pdf》由会员分享，可在线阅读，更多相关《艾昆纬&Reset Health：2025英国抗肥胖药物临床应用的成本控制与服务优化白皮书（英文版）（13页）.pdf（13页珍藏版）》请在三个皮匠报告上搜索。

1、April 2025From costly to cost-effective:rethinking commissioning of anti-obesity medicationsA Reset Health&IQVIA collaboration:Bringing together industry-leading digital weight management support with the worlds leading clinical research and healthcare data company to deliver a sustainable and effec

2、tive weight management service.2April 2025Copyright 2025 Reset Health Ltd&IQVIAINTRODUCTIONTHE CHALLENGE OF OBESITYForecastsNICE and NHSEs recommendations for anti-obesity medicationsLicensing recommendationsWhy are ICBs concerned?Capacity in primary and secondary care settingsHOW CAN WE MAKE IT WOR

3、K?Collaborating locally with primary careSupporting clinical delivery in primary careUtilising digital health servicesThe IQVIA and Reset Health Community Obesity Management ServiceCONCLUSIONContact344556788910111213Contents3April 2025Copyright 2025 Reset Health Ltd&IQVIAIntroductionObesity is a gro

4、wing problem for the UK placing significant pressure not only on population health and NHS services but also on the wider economy.Recent pharmacological developments mean that we now have more treatments to help manage obesity than ever before,alongside existing dietary and behavioural interventions

5、 in specialist weight management services.Whilst these existing services are traditionally patchy and struggle with capacity,it is hoped these new medications will improve patient outcomes and reduce the pressures of obesity on wider society.With recent NICE recommendations for these pharmacotherapi

6、es,Integrated Care Boards(ICBs)have been told they will be expected to roll them out to all eligible patients.However,many ICBs have expressed concerns regarding the affordability of these new therapies,and the lack of capacity to provide wrapa-round support in both secondary and primary care settin